We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Fulcrum Therapeutics Starts Phase 3 Trial of Muscle Disorder Drug for COVID-19
Fulcrum Therapeutics Starts Phase 3 Trial of Muscle Disorder Drug for COVID-19
Fulcrum Therapeutics has begun a phase 3 clinical trial in the U.S. of its investigational anti-inflammatory drug losmapimod for the treatment of hospitalized COVID-19 patients.